Solutions
Advisory Services
Clinical Development
- Generics Development
- Clinical Operations
- Clinical Data Sciences
- Medical and Safety Services
- RWD & RWE Services
Post Marketing
- Safety Services
- Post marketing Studies
- Regulatory Affairs
On April 7, 2025, we join the World Health Organisation, under the banner of Healthy beginnings, hopeful futures. The World Health Day 2025 campaign urges stakeholders to take decisive action against preventable maternal and newborn deaths. Over 300,000 women lose their lives annually due to pregnancy or childbirth, and 4 million newborns die or ar...
The pharmaceutical industry is experiencing a paradigm shift in medical writing, driven by artificial intelligence (AI), structured content authoring, and automation. Navitas Life Sciences’ 3rd Medical Writing Roundtable, hosted by Dr Latika Sharma and Dr. Sara Giadrossi, brought together industry leaders from 10+ global pharmaceutical compa...
The pharmaceutical industry is undergoing a significant transformation driven by digital innovation and artificial intelligence (AI). It has become increasingly beneficial to leverage AI powered tools and cloud based regulatory solutions to streamline regulatory submissions. These advancements enhance efficiency, improve data exchange, and ensure c...
The global generics market is on an accelerated growth path, with the U.S. leading the way, projected to surpass USD 508.37 billion by 2034 at a CAGR of 12.00%. This momentum is driven by rising healthcare costs, expiring patents, and increasing regulatory support for generic drug approvals. However, growth brings complexity. Regulatory scrutiny is...
Ensuring Compliance with the Windsor Framework The Windsor Framework is now implemented, transforming the regulatory landscape for pharmaceutical companies operating in the UK. While the framework simplifies processes by enabling a UK-wide licensing system under the Medicines and Healthcare products Regulatory Agency (MHRA), companies that have not...
At Navitas Life Sciences, we stand as a leading oncology CRO, delivering cutting edge solutions that optimize trial design, enhance patient recruitment, and accelerate regulatory approvals. With over 100 oncology clinical studies conducted, we bring deep expertise in solid and hematological tumors, including breast, lung, gastric, HCC, prostate, mu...
What is a CRO? A Contract Research Organization (CRO) is a strategic partner to pharmaceutical, biotechnology, and medical device companies, providing outsourced research activities that facilitate the efficient execution of clinical trials and regulatory processes. CROs offer expertise across clinical development, regulatory affairs, pharmacovigil...
Glaucoma remains a leading cause of irreversible blindness worldwide, affecting millions of people and posing significant challenges for healthcare systems. Despite advancements in diagnostics and treatment, the complexity of the disease—characterized by its silent progression and multifactorial nature—demands a continuous evolution i...
The US Food and Drug Administration (FDA) recently provided a draft guidance on the application of artificial intelligence (AI) in regulatory decision making. By championing a balance between innovation and safety, this initiative highlights the significance of AI while upholding its rigorous scientific and regulatory standards. Entitled ‘Co...
The clinical trials landscape in 2025 is shaped by technological advancements, regulatory shifts, and a growing demand for innovative therapies. In our latest blog we explore key developments that are poised to leave a lasting impact on clinical trials. 1. AI and Machine Learning: Moving from Hype to Practical Applications Artificial Intelligence (...